Payment overview · 2025
General Payments
$826.06
44 reported records · 19 companies
Healthcare provider profile · identity verified
John R Rocchi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BUTLER, PA · NPI 1306837091
Verified facts
What the public records show
CMS Open Payments records show John R Rocchi, MD received $826.06 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ingrezza, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 411 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 886 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $157.37 | 19.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $106.74 | 12.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.29 | 10.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.49 | 9.9% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.05 | 6.4% | 2 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $38.21 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.90 | 4.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.88 | 4.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.72 | 4.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.00 | 3.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.48 | 3.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $26.51 | 3.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.16 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.01 | 1.9% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $15.84 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.63 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.38 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.37 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.03 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $787.52 | 43 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.26 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.05 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.48 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.32 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $67.43 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.79 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.79 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $38.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.00 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.48 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 886 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
58 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
411 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
99 | 17 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
886 | 76 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2207 | 176 |
| Gabapentin | Gabapentin | 1781 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 1409 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1349 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1259 | 123 |
| Furosemide | Furosemide | 1069 | 85 |
| Sertraline Hcl | Sertraline Hcl | 953 | 62 |
| Eliquis | Apixaban | 886 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 865 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 855 | 126 |
| Duloxetine Hcl | Duloxetine Hcl | 840 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 788 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 764 | 92 |
| Lisinopril | Lisinopril | 752 | 87 |
| Potassium Chloride | Potassium Chloride | 716 | 61 |
| Metformin Hcl | Metformin Hcl | 680 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 676 | 52 |
| Omeprazole | Omeprazole | 653 | 92 |
| Losartan Potassium | Losartan Potassium | 634 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 535 | 23 |
| Tradjenta | Linagliptin | 513 | 33 |
| Trazodone Hcl | Trazodone Hcl | 492 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 475 | 53 |
| Simvastatin | Simvastatin | 434 | 50 |
| Jardiance | Empagliflozin | 411 | 51 |
| Bumetanide | Bumetanide | 386 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 369 | 42 |
| Aripiprazole | Aripiprazole | 363 | suppressed |
| Carvedilol | Carvedilol | 363 | 25 |
| Risperidone | Risperidone | 328 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 322 | 51 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 317 | 16 |
| Mirtazapine | Mirtazapine | 314 | 29 |
| Olanzapine | Olanzapine | 298 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 268 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 268 | 16 |
| Allopurinol | Allopurinol | 263 | 34 |
| Buspirone Hcl | Buspirone Hcl | 262 | 27 |
| Levetiracetam | Levetiracetam | 250 | suppressed |
| Myrbetriq | Mirabegron | 250 | 19 |
| Donepezil Hcl | Donepezil Hcl | 245 | 14 |
| Finasteride | Finasteride | 244 | 21 |
| Xarelto | Rivaroxaban | 242 | 23 |
| Baclofen | Baclofen | 236 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 236 | 14 |
| Meloxicam | Meloxicam | 228 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 216 | 17 |
| Celecoxib | Celecoxib | 212 | 42 |
| Irbesartan | Irbesartan | 210 | 43 |
| Montelukast Sodium | Montelukast Sodium | 202 | 20 |
| Bupropion Xl | Bupropion Hcl | 185 | 11 |
| Lorazepam | Lorazepam | 185 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 12 |
| Divalproex Sodium | Divalproex Sodium | 172 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 168 | 31 |
| Alendronate Sodium | Alendronate Sodium | 166 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 150 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 149 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 145 | 18 |
| Valsartan | Valsartan | 144 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 140 | 14 |
| Methocarbamol | Methocarbamol | 140 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 135 | suppressed |
| Sucralfate | Sucralfate | 133 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 122 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 47 |
| Prednisone | Prednisone | 118 | 41 |
| Topiramate | Topiramate | 114 | suppressed |
| Calcitriol | Calcitriol | 110 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 109 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 23 |
| Warfarin Sodium | Warfarin Sodium | 107 | 15 |
| Farxiga | Dapagliflozin Propanediol | 106 | suppressed |
| Entresto | Sacubitril/Valsartan | 104 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 104 | suppressed |
| Ozempic | Semaglutide | 102 | 20 |
| Tramadol Hcl | Tramadol Hcl | 102 | 30 |
| Glipizide | Glipizide | 99 | 27 |
| Trulicity | Dulaglutide | 99 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 98 | 24 |
| Midodrine Hcl | Midodrine Hcl | 95 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 11 |
| Ezetimibe | Ezetimibe | 92 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 91 | suppressed |
| Digoxin | Digoxin | 90 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 23 |
| Synthroid | Levothyroxine Sodium | 90 | 25 |
| Januvia | Sitagliptin Phosphate | 86 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 79 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 74 | suppressed |
| Cephalexin | Cephalexin | 73 | 28 |
| Metformin Hcl Er | Metformin Hcl | 73 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 71 | suppressed |
| Ranolazine Er | Ranolazine | 71 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 69 | suppressed |
| Glimepiride | Glimepiride | 67 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 56 |
| Glipizide Er | Glipizide | 65 | 11 |
| Mesalamine | Mesalamine | 65 | suppressed |
| Azithromycin | Azithromycin | 64 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 14 |
| Spironolactone | Spironolactone | 64 | 13 |
| Glycopyrrolate | Glycopyrrolate | 61 | suppressed |
| Clonazepam | Clonazepam | 60 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 32 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 58 | 58 |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | suppressed |
| Repaglinide | Repaglinide | 56 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | 13 |
| Doxepin Hcl | Doxepin Hcl | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 18 |
| Latanoprost | Latanoprost | 55 | suppressed |
| Methylprednisolone | Methylprednisolone | 53 | 45 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 53 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | suppressed |
| Phenytoin | Phenytoin | 52 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 50 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 50 | suppressed |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 31 |
| Metolazone | Metolazone | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 43 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Atenolol | Atenolol | 43 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Famotidine | Famotidine | 42 | 12 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 39 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Acetic Acid | Acetic Acid | 38 | suppressed |
| Jantoven | Warfarin Sodium | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 35 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 34 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 29 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Olanzapine Odt | Olanzapine | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 22 |
| Dutasteride | Dutasteride | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Ingrezza | Valbenazine Tosylate | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 13 |
| Linzess | Linaclotide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 20 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $826.06 · 44 records | Novo Nordisk Inc | ABRYSVO, BEXSERO, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, INGREZZA, INSPIRE, M-M-R II, MOUNJARO, Monarch Platform, NURTEC ODT, Natroba, OTEZLA, Ozempic, PAXLOVID, PENMENVY, PREVNAR 20, PROCLAIM, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, Spinosad, TRELEGY ELLIPTA, UBRELVY, VAXNEUVANCE, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error